Free Newsletter
Scripps Research team finds new obesity target
A team of investigators at the Scripps Research Institute say they've identified a catalytic antibody that works against ghrelin, a gastric hormone that plays a key role in fat storage and weight gain. The scientists say that the antibody could offer a new tool to fight obesity by targeting the biologic mechanisms that trigger weight gain.
"Our study showed that this novel catalytic ghrelin antibody could specifically seek out and degrade ghrelin," said Kim Janda, director of the Worm Institute of Research and Medicine at Scripps Research. "While this antibody lacks a high level of catalytic efficiency, our study clearly demonstrates that even a basal level of catalysis can effectively modulate feeding behavior. These findings not only validate antibody-based therapeutics, but strongly suggest that catalytic anti-ghrelin antibodies might help patients reach and maintain their weight loss goals."
The new study is being published online the week of October 27, 2008, in an advance early edition of the journal Proceedings of the National Academy of Sciences.
- read the Scripps release
Related Articles:
Scripps researchers find anti-obesity vaccine (Aug 2006)
Scripps to study how people react to genetic data
Scripps to build HIV research center
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: